Clinical trial · Interventional
Adjunctive Donepezil Therapy and Genetic Risk Factors of Cognitive Dysfunction in Brain Tumor Survivors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A significant number of brain tumor patients who received radiation or chemotherapy have thinking problems as a result of their treatment. The purpose of this study is to find out if treatment with Aricept (donepezil) may improve some aspects of thinking abilities in patients with brain tumors who received radiation or chemotherapy. This research will also study whether persons having particular genes for a blood-borne substance called apolipoprotein E (APOE) are more likely to have thinking problems after radiation or chemotherapy treatment for their brain tumors. The findings of this study will help us find out whether Aricept can improve thinking abilities after cancer treatment, and whether some of the thinking difficulties may be in part related to having certain genes.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Cancer | Malignant Brain Neoplasm | ALIAS | 0.90 |
| Brain Tumor | Brain Neoplasm | ALIAS | 0.90 |
| Cns Cancer | Malignant Central Nervous System Neoplasm | ALIAS | 0.90 |
| Cognitive Dysfunction | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| donepezil and questionaires | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- description
- donepezil and questionaires
- interventionNames
- Other: donepezil and questionaires
Primary outcomes (1)
- measure
- The primary goal of this study is to assess the efficacy of donepezil in improving executive abilities and psychomotor speed in adult brain tumor patients who have undergone cranial irradiation and/or chemotherapy.
- timeFrame
- conclusion of study
Secondary outcomes (2)
- measure
- This study will also assess the efficacy of donepezil in improving other cognitive domains such as attention, memory, and general cognition in this population.
- timeFrame
- conclusion of study
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * diagnosed with a brain tumor and treated with cranial irradiation and/or chemotherapy, and in stable remission of their disease at the time of enrollment. * completed radiation and/or chemotherapy treatment at least 6 months prior to being enrolled in the study. * who obtain a Mini-Mental Status Examination (MMSE) score ranging from 18 to 28 at the time of enrollment. * are at least 18 years of age. * are English speaking. * have capacity to give consent Exclusion Criteria: * Patients with active or progressive disease on recent MRI of the brain either at the time of enrollment, or during the study period. * with a pre-existing uncontrolled seizure disorder, or significant renal or hepatic impairment. * taking the following medications: antipsychotics, psychostimulants. * patients who have been on selective serotonin re-uptake inhibitors (SSRIs) for less than 3 months at the time of enrollment. * with uncontrolled behavioral or mood disturbances. * have their anticonvulsant medication(s) or dosage(s) changed less than 30 days prior to enrollment. * currently receiving donepezil or other cholinesterase inhibitors. * who is pregnant. * unable to cooperate or complete cognitive tests.
References
Publications (0)
Data not yet available